Business Wire

BALDERTON-CAPITAL

10.6.2021 10:02:29 CEST | Business Wire | Press release

Share
Balderton Capital Expands, Launching $680M ‘Early Growth’ Fund to Invest in Future Tech Giants Born in Europe

Two decades in European tech

After more than 20 years focused on backing Europe’s most ambitious early-stage founders, Balderton Capital is launching a dedicated growth fund to extend its support to European founders scaling the next global tech giants.

While this is the first time the firm has expanded to a completely new stage of primary investing, Balderton already holds one of the largest growth stage portfolios in Europe, having backed some of Europe’s most successful startups from a very early stage. The firm invested at Seed or Series A in global leaders Aircall, ComplyAdvantage, Contentful, Depop, GoCardless, Infarm, Labster, Revolut, THG, Vestiaire Collective and Zego. The firm’s Liquidity I portfolio also includes some of Europe’s leading growth companies, such as Darktrace, Flywire, Graphcore and Truecaller.

Balderton predicts a formidable increase in the European growth stage opportunity

Balderton sees an unprecedented opportunity for growth stage investing in Europe. Along with a maturing technology ecosystem, market disruption caused by the coronavirus pandemic has favoured innovation. The number of deals between $5m and $50m in Europe has been growing steadily year-on-year, with deal counts in those ranges now accelerating faster than in the US. Ten years ago, the US was doing five times the number of venture deals compared to Europe. Today that ratio has more than halved.1 All indications point to more high quality European companies reaching a stage of maturity where they need experienced European growth capital.

“I’ve been an investor at Balderton since 2008, and it has been incredible to see the increasing number of ambitious European founders, and to be able to support them financially through those critical first three to five years with our early stage funds. With this Growth Fund, we can now support them as they scale to become global industry leaders. We predict a $50 billion growth opportunity in Europe in the next three years alone, and we want to be the first choice for those ambitious founders,” said Bernard Liautaud, Managing Partner.

The fund will target exceptional companies at the early-growth stage and is sector-agnostic. Balderton expects to invest between $25m and $50m per company through both primary and secondary investments.

Rana Yared, General Partner, adds: “Our approach for this fund will be ‘one of few’. This means personalised attention from the entire partnership, plus access to Balderton’s leading platform team. We’re looking for fifteen or so really exceptional companies that have the potential to be sector leaders and disrupt global industries.”

World-class growth team

Balderton Growth I will be led by a world-class team of experienced investor operators: Balderton’s Managing Partner, Bernard Liautaud ; General Partner David Thévenon , previously at Google and Softbank; and General Partner Rana Yared , previously at Goldman Sachs. This team brings exceptional experience to share with Founders, having been on the board of global giants across Europe, Asia and the US, including Grab, SoFi, Lemonade, Talend, THG, Tradeweb and Unqork .

Balderton’s Growth team will also be supported by the firm’s equal Partnership . Balderton’s Partners are equally vested in every Portfolio company’s success, and all Founders benefit from access to the full team’s experience and support.

Portfolio leadership teams will also have access to Balderton’s wider team, which has now grown to over 50, including functional specialists in marketing, talent, legal and finance, and 23 investors across key European hubs including London, Berlin, Paris and Stockholm.

David Thévenon, General Partner at Balderton said: “We have been lucky enough to have spent the past two decades deeply embedded in the European tech ecosystem, working with hundreds of extraordinary founders. Our partners are a mixture of financiers, tech operators and founders themselves, and together we have a deep understanding of the opportunities and challenges of scaling globally from the continent. This fund will allow us to expand our support, not only to our existing portfolio but also to Europe’s most promising future global leaders.”

Building on momentum

This fund follows Balderton’s launch of Europe’s first dedicated secondary fund, Liquidity I in 2018, and the firm’s seventh Series A fund in 2019 , and it comes after a record year for both Balderton and its portfolio.

In the 18 months since January 2020, 22 new companies have joined the Balderton portfolio, and the firm has made over 45 follow-on investments. There have been three IPOs, with THG in 2020 , (the second most valuable technology IPO in Europe); Darktrace in 2021 ; and Flywire in 2021 . The firm has also seen eleven portfolio exits since January 2020, including Digital Surgery’s acquisition by Medtronic , Peakon’s acquisition by Workday and Depop’s acquisition by Etsy .

In addition, companies in the Balderton portfolio have themselves raised more than $5bn since January 2020 to fuel growth, of which close to $1.7bn has been since the beginning of 2021. The portfolio now employs over 25,000 staff in over 50 countries around the world.

- ENDS -

About Balderton Capital

Balderton Capital is Europe’s leading venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since its founding, Balderton has worked with hundreds of extraordinary European founders, and has raised 4$bn across nine funds. Previous exited investments include Betfair (FTSE: BET), Depop (Etsy), Digital Surgery (Medtronic), Frontier Car Group (OLX Group), Magic Pony (Twitter), NaturalMotion (Zynga), Peakon (Workday), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Balderton’s current portfolio includes: Aircall, Carwow, Citymapper, Contentful, ComplyAdvantage, Darktrace (LON: DARK), Flywire (NASDAQ: FLYW), GoCardless, Graphcore, Infarm, Kobalt Music, Nutmeg, Prodigy Finance, Revolut, SOPHiA Genetics, Tessian, THG (LON: THG), VanMoof, Vestiaire Collective, Vivino and Zego.

For more information see http://www.balderton.com or follow @balderton.

1 Source: Pitchbook

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye